AbbVie Inc. (ABBV)

Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NYSE
Market cap: $501.19B
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Latest financial period: September 30, 2026
Filed with the SEC: November 3, 2026
Estimated earnings date: Not available
Profit #237 of 1422 companies
| | Sep 26 | Jun 26 | Mar 26 | Dec 25 |
|---|
| ROIC | 22.8% | 19.1% | 16.0% | 15.6% |
Growth #822 of 1422 companies
Payout #951 of 1422 companies
Safety #1101 of 1422 companies
Price #1035 of 1422 companies